Facilitated By

San Antonio Medical Foundation

News

  • Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 ...

    Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of ... HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio ...

  • Senhwa Biosciences Reports Positive Phase 1 Data of CX-5461 in Patients With Advanced Solid ...

    Phase 1 clinical findings were featured within a spotlighted presentation at the annual 2019 San Antonio Breast Cancer Symposium (SABCS) by ...

  • The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix ...

    The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls ... Puma Biotechnology Inc (NASDAQ: PBYI) presented at the San Antonio ...

  • Updated APHINITY Supports Benefit of Dual HER2 Blockade

    SAN ANTONIO, Texas — An updated analysis of the APHINITY trial .... G1 Therapeutics, Huya Bioscience International, Immunomedics, Eli Lilly, The ...

  • Brown, Edwards, Matros, McCown and Studdard win 11th annual Ouachita Business Plan ...

    Michael Neathery, a senior biology major from San Antonio, Texas; Beau Pennington, a junior biomedical sciences major from Bee Branch, Ark.; Tyler ...